Bortezomib

Bortezomib is a medication used in the treatment of multiple myeloma and mantle cell lymphoma. It belongs to a class of drugs known as proteasome inhibitors.

Bortezomib works by inhibiting the activity of proteasomes, which are cellular structures involved in the breakdown of proteins. By blocking the proteasome function, bortezomib disrupts the normal protein degradation process in cancer cells, leading to their accumulation and ultimately causing cell death.

The medication is typically administered intravenously or subcutaneously and may be used alone or in combination with other chemotherapy drugs. The specific dosage and treatment regimen are determined by the healthcare provider based on the individual’s condition, response to therapy, and other factors.

Common side effects of bortezomib may include fatigue, nausea, diarrhea, peripheral neuropathy (numbness or tingling in the extremities), and low blood cell counts. More serious side effects, such as heart problems or liver toxicity, can occur but are less common. Regular monitoring of blood cell counts, liver function, and other parameters may be recommended during treatment.

Bortezomib should only be used under the guidance and prescription of a qualified healthcare professional experienced in the treatment of multiple myeloma or mantle cell lymphoma. It may interact with other medications, so it is important to inform the healthcare provider about all medications being taken, including over-the-counter drugs and supplements.

In summary, bortezomib is a medication used in the treatment of multiple myeloma and mantle cell lymphoma. It inhibits proteasome activity to cause the accumulation of proteins in cancer cells, leading to their death. Regular monitoring and adherence to healthcare provider instructions are important during bortezomib treatment.

Note – The brand names and product descriptions used on this site are for informational purposes only and are the property of their respective owners.